(Q38110696)

English

Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme

scientific article published on 30 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Hester E. de Melker

6

object named as

Hester E de Melker

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Chris J L M Meijer

5

object named as

Chris J L M Meijer

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

author name string

Madelief Mollers

1

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Jeanique M Vossen

2

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Mirte Scherpenisse

3

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Fiona R M van der Klis

4

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

publication date

30 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Journal of Medical Virology

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

85

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

1379-1385

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

The epidemiology of human papillomavirus infections

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

The papillomavirus life cycle

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

The need for serologic evaluation of immunization programs

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

The known unknowns of HPV natural history

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Natural history of cervicovaginal papillomavirus infection in young women.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Natural history of human papillomavirus type 16 virus-like particle antibodies in young women

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Epidemiologic Factors Associated with Seropositivity to Human Papillomavirus Type 16 and 18 Virus-Like Particles and Risk of Subsequent Infection in Men

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Determinants of seropositivity among HPV-16/18 DNA positive young women

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Changes in antibody seroprevalence of seven high-risk HPV types between nationwide surveillance studies from 1995-96 and 2006-07 in The Netherlands

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Serological detection of human papillomavirus type 16 infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Immune responses to human papillomavirus

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: the International Agency for Research on Cancer HPV Prevalence Surveys.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Cellular Immunity in Measles Vaccine Failure: Demonstration of Measles Antigen-Specific Lymphoproliferative Responses despite Limited Serum Antibody Production after Revaccination

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Low-level persistence of human papillomavirus 16 DNA in a cohort of closely followed adolescent women.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Evaluation of Seroreactivity to Human Papillomavirus Type 16 Virus-like Particles in an Incident Case-Control Study of Cervical Neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and-negative women

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Epidemiologic correlates of antibody response to human papillomavirus among women at low risk of cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23616

21 January 2018

Identifiers

10.1002/JMV.23616

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38110696&oldid=2135052365"